Skip to content
HowShorted

AERIE PHARMACEUTICALS INC short interest in 2018

In 2018, AERIE PHARMACEUTICALS INC's disclosed short interest ran from 10.76% of shares outstanding on 12 Jan 2018 to 8.99% on 31 Dec 2018, a change of -1.77 percentage points. The year's high was 16.32% on 13 Jul 2018 and its low 8.25% on 14 Dec 2018, averaging 11.74% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.95 days on 30 Apr 2018. Full history: AERIE PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for AERIE PHARMACEUTICALS INC in 2018

2018 in figures

Start of year
10.76% (12 Jan 2018)
End of year
8.99% (31 Dec 2018)
Change
-1.77 pp
High
16.32% (13 Jul 2018)
Low
8.25% (14 Dec 2018)
Average
11.74%
Highest days to cover
29.95 (30 Apr 2018)
SEC filings marked
9

Every report in 2018

AERIE PHARMACEUTICALS INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201810.76%14.61
31 Jan 201810.72%8.05results (8-K)
15 Feb 201810.33%11.04
28 Feb 201810.08%12.72results (8-K)
15 Mar 201811.47%12.3710-K filed
29 Mar 201813.15%13.76
13 Apr 201814.61%21.70
30 Apr 201814.88%29.95
15 May 201814.90%15.45results (8-K), 10-Q filed
31 May 201815.03%22.44
15 Jun 201815.05%10.22
29 Jun 201816.01%12.52
13 Jul 201816.32%16.84
31 Jul 201810.93%13.00
15 Aug 20189.67%11.57results (8-K), 10-Q filed
31 Aug 20189.17%8.81
14 Sep 20189.36%12.66
28 Sep 201810.27%8.78
15 Oct 201811.17%11.44
31 Oct 201811.47%10.41
15 Nov 201810.12%5.18results (8-K), 10-Q filed
30 Nov 20189.07%7.39
14 Dec 20188.25%7.31
31 Dec 20188.99%6.49

See also: AERIE PHARMACEUTICALS INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.